Cannara Biotech Inc.
LOVFF
$0.9125
$0.00610.67%
OTC PK
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 27.49% | 23.90% | 22.42% | 53.67% | 87.29% |
| Total Other Revenue | -- | 66.78% | -28.19% | -- | -- |
| Total Revenue | 27.49% | 24.72% | 22.11% | 53.67% | 87.29% |
| Cost of Revenue | 31.40% | 45.21% | 70.69% | 77.88% | 102.69% |
| Gross Profit | 22.12% | 6.61% | -19.38% | 1.52% | 69.56% |
| SG&A Expenses | 30.68% | 40.55% | 27.56% | 81.74% | 30.63% |
| Depreciation & Amortization | -31.90% | 280.44% | -8.59% | -18.42% | 37.41% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.94% | 44.62% | 54.04% | 75.73% | 73.21% |
| Operating Income | 20.65% | -19.29% | -64.77% | -513.92% | 204.40% |
| Income Before Tax | 42.89% | -20.16% | -31.21% | -460.01% | 70,054.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.60% | 20.91% | -31.21% | -460.01% | 70,054.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.60% | 20.91% | -31.21% | -460.01% | 70,054.55% |
| EBIT | 20.65% | -19.29% | -64.77% | -513.92% | 204.40% |
| EBITDA | 12.41% | -10.41% | -46.63% | -136.23% | 118.41% |
| EPS Basic | 8.77% | 24.53% | -30.67% | -448.08% | -- |
| Normalized Basic EPS | 42.99% | -21.82% | -100.67% | -496.67% | 5,250.00% |
| EPS Diluted | 27.40% | 20.00% | -33.48% | -302.70% | -- |
| Normalized Diluted EPS | 42.45% | -23.18% | -100.68% | -496.67% | 5,200.00% |
| Average Basic Shares Outstanding | -0.22% | -2.83% | -0.72% | 1.89% | 2.85% |
| Average Diluted Shares Outstanding | 0.62% | -1.20% | 0.13% | 1.89% | 3.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |